Current Landscape in the Systemic Treatment of Hepatobiliary Cancers: From Neoadjuvant Strategies to Advanced Disease

In this commentary, experts provide answers to questions from healthcare professionals on best practices in managing patients with HCC, with specific emphasis on the use of targeted and immunotherapies.

Richard S. Finn, MD Amit G. Singal, MD, MS Mark Yarchoan, MD Released: January 3, 2022

Download this slideset for expert perspectives on best practices and emerging strategies in using immune checkpoint inhibitor combinations for patients with advanced hepatocellular carcinoma.

Richard S. Finn, MD Amit G. Singal, MD, MS Released: November 12, 2021

Download this slideset for expert perspectives on emerging strategies in using immune checkpoint inhibitor combinations for patients with early- and intermediate-stage hepatocellular carcinoma.

Amit G. Singal, MD, MS Released: November 12, 2021

Download this slideset for expert perspectives on best practices and emerging strategies in using immune checkpoint inhibitors and targeted therapies to treat patients with advanced biliary tract cancers.

Mark Yarchoan, MD Released: November 12, 2021

Download this short summary slideset of key takeaway points on using immune checkpoint inhibitors and targeted therapies for patients with hepatocellular carcinoma and biliary tract cancers.

Richard S. Finn, MD Amit G. Singal, MD, MS Mark Yarchoan, MD Released: November 18, 2021